{"filing":{"accession_number":"0001493152-26-034601","cik":"0001582554","ticker":"MTNB","company_name":"Matinas BioPharma Holdings, Inc.","form":"8-K","filing_date":"2026-07-24","report_date":"2026-07-23","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1582554/000149315226034601/form8-k.htm"},"events":[{"id":20524,"run_id":18466,"accession_number":"0001493152-26-034601","anchor_item_number":null,"event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"The filing discloses termination of an At-The-Market (ATM) Sales Agreement with BTIG, effective July 23, 2026. The agreement had authorized up to $50 million in equity offerings. While the termination itself carries no penalties, loss of an ATM facility materially affects the company's capital-raising flexibility and liquidity options, making it material to investors assessing the registrant's financial position and access to capital.","company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","filing_date":"2026-07-24","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":19898,"accession_number":"0001493152-26-034601","item_number":null,"item_title":null,"event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses termination of an At-The-Market (ATM) Sales Agreement with BTIG, effective July 23, 2026. The agreement had authorized up to $50 million in equity offerings. While the termination itself carries no penalties, loss of an ATM facility materially affects the company's capital-raising flexibility and liquidity options, making it material to investors assessing the registrant's financial position and access to capital.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T21:02:07.864609+00:00","company_name":"Matinas BioPharma Holdings, Inc.","ticker":"MTNB","filing_date":"2026-07-24"}]}